{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:20:36Z","timestamp":1763018436190,"version":"3.41.2"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1200\/op.21.00486","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T15:59:17Z","timestamp":1630079957000},"page":"114-115","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Evolving Treatment Paradigm in Frontline CLL"],"prefix":"10.1200","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00258"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1908213"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7523"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7509"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O Zhang C Tandon M et al: Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter open-label randomized phase 3 CLL14 trial. European Hematology Association Annual Meeting 2021 (abstr S155)","DOI":"10.1200\/JCO.2020.38.15_suppl.8027"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_4_11_2","unstructured":"Hillmen P Eichhorst B Brown J et al: First interim analysis of alpine study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. European Hematology Association Annual Meeting 2021 (abstr LB1900)"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1649"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134446"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7501"},{"key":"e_1_3_4_16_2","unstructured":"Kater A Owen C Moreno C et al: Fixed-duration ibrutinib and venetoclax (i+v) versus chlorambucil plus obinutuzumab (clb+o) for first-line (1l) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. European Hematology Association Annual Meeting 2021 (abstr LB1902)"},{"key":"e_1_3_4_17_2","first-page":"360","article-title":"How I manage chronic lymphocytic leukemia","volume":"19","author":"Jain N","year":"2021","unstructured":"Jain N: How I manage chronic lymphocytic leukemia. Clin Adv Hematol Oncol 19:360-364, 2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140622"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.21.00486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:29:29Z","timestamp":1752604169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.21.00486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1200\/OP.21.00486"],"URL":"https:\/\/doi.org\/10.1200\/op.21.00486","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"type":"print","value":"2688-1527"},{"type":"electronic","value":"2688-1535"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}